| Revenue growth | Q4FY26 up 22% QoQ, 17% YoY. |
|---|---|
| Margins | EBITDA margins improved to 23% in Q4 from 17% in Q3. |
| Demand visibility | Strong recovery in Q4; addressable market growing 10-13% over 5 years. |
| Management confidence | High; citing demand recovery since November and momentum into FY27. |
Growth
Q4FY26 PAT rose 109% QoQ to ₹82 Cr. FY26 revenue slightly dipped 1% to ₹2,542 Cr.
Outlook
Capex of ₹400 Cr planned for FY27; major CPVC and Epichlorohydrin expansions commissioning in Q2FY27.
Risks
Profitability impacted by increased raw material prices and lower utilization earlier in FY26 due to extended monsoon.
Earnings Call filed with BSE, NSE: EPIGRAL. Summary written with AI assistance from the document.
Epigral Ltd: key numbers
- Share price
- ₹1,036.20
- Market cap
- ₹4,470 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 16.5×Sector 37.2×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 1.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Earnings Call Transcript: Key Takeaways
Epigral reported 15% revenue growth and 25% EBITDA margins despite Red Sea logistical disruptions. Management is pivoting toward high-value downstream specialty chemicals like Epoxy resins to reduce commodity exposure.
- Call
- Guides 20% growth
Epigral Capacity Expansion: ₹650 Cr Investment
Epigral Ltd will invest ₹650 Crore to add 1,25,000 TPA of Epoxy Resin & Formulations capacity at its Dahej facility, expected by H2 FY2028.
- Value
- ₹650.0 Cr
- Execution
- By H2 FY2028
Epigral Investor Presentation: Key Takeaways
Epigral reported 15% YoY revenue growth and 25% PAT growth for Q1FY27. Strategy focuses on diversifying into high-value derivatives and specialty chemicals with significant capex for Epoxy Resin and Multi-Purpose plants.
- Call
- Guides 70% growth
Epigral Results Update
Epigral reported Q1FY27 PAT of ₹99 Crore, a 25% YoY increase. The company plans ₹600 Crore capex for Epoxy Resin and Multi-Purpose Plant.
- Value
- ₹600.0 Cr
- Execution
- H2FY28
Epigral Capacity Expansion: ₹600 Cr Investment
Epigral Limited plans to establish a new manufacturing facility for Epoxy Resin and Multi-Purpose Plant at Dahej, Gujarat. The project requires an investment of ₹600 Crore.
- Value
- ₹600.0 Cr
- Execution
- By H2 FY2028
Epigral Q1 FY27 Results: Net Profit ₹99.7 Cr, Down 38.0% YoY
Epigral Ltd reported revenue from operations of ₹705.4 Cr (+16.3% YoY) and net profit of ₹99.7 Cr (-38.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹99.7 Cr · -38.0% YoY